Neuronetics (STIM) Fundamentals 2026 — Revenue Analysis | SniperIQ
Neuronetics (STIM) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Neuronetics's market cap?
Neuronetics (STIM) has a market capitalization of approximately
What is Neuronetics's P/E ratio?
Neuronetics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Neuronetics?
Neuronetics runs a net profit margin of -24.5%, a gross margin of 48.0%, and an operating margin of -19.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Neuronetics generate?
Neuronetics reported revenue of
Does Neuronetics pay a dividend?
Neuronetics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Neuronetics financially healthy?
Neuronetics carries a debt-to-equity ratio of 6.44x and a current ratio of 1.67x, with a market beta of 1.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Neuronetics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Neuronetics (STIM) the key facts are: market cap
Track Neuronetics's full fundamentals live
Get Neuronetics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.